STEP Young reported that 40.4% of children ages 6–11 treated with semaglutide and lifestyle support moved below the obesity threshold at 68 weeks. Here is what the topline result means, what remains unknown and what families should track with a specialist.
Semaglutide is already part of the obesity-treatment conversation for adults and adolescents. Now a new trial has moved that conversation into a younger age group.
On September 7, 2026, Novo Nordisk announced topline results from STEP Young, a phase 3 trial in children ages 6 to under 12 living with obesity. The headline result was striking: after 68 weeks, 40.4% of children assigned to semaglutide were no longer classified as having obesity, compared with 0% assigned to placebo, using the trial’s on-treatment analysis.
That number deserves attention. It also needs context. The company has not yet released the trial’s full data, the results have not yet been presented in detail, and semaglutide is not currently established as a weight-management treatment for children under 12 in the United States. A topline announcement can tell us that a study met its main goal; it cannot answer every question families and clinicians need to ask.
Here is what STEP Young found, what remains unknown and how families can prepare for a more useful conversation with a pediatric obesity specialist.
STEP Young was a randomized, double-blind, placebo-controlled phase 3 trial conducted across multiple countries. It enrolled 165 children ages 6 to under 12 who were living with obesity. More than 85% had class II or class III severe obesity at the beginning of the study, so this was a group with substantial disease severity.
Participants were randomly assigned to receive either once-weekly semaglutide or placebo. The maximum semaglutide dose was based on starting weight and was either 1.7 mg or 2.4 mg. Both groups also received support for a reduced-calorie diet and increased physical activity.
The main endpoint was the percentage change in body mass index, or BMI, from the start of the trial to week 68. Novo Nordisk reported that semaglutide produced a statistically superior reduction in BMI compared with placebo, meaning the trial met its primary goal. The company did not include the exact average BMI change in its initial announcement.
The most widely discussed number from the announcement is that 40.4% of children in the semaglutide group were no longer classified as having obesity at week 68. No children in the placebo group crossed below that threshold in the same analysis.
This does not mean that 40.4% reached an “ideal weight,” nor does it mean that obesity was permanently cured. It means their BMI moved below the age- and sex-specific threshold used to define obesity at that time point.
The result came from what the sponsor calls a trial product estimand. In practical terms, this analysis asks what happened if participants stayed on their assigned treatment as planned. That is useful for estimating a medication’s effect under continued use, but it can differ from a treatment-policy analysis that includes outcomes after discontinuation or imperfect adherence. The detailed presentation should clarify both analyses, how many participants completed treatment and how missing data were handled.
It is also a group-level result. Some children may have had a large response, some a modest response and some little or no response. An average or threshold result cannot predict what will happen for an individual child.
Adult BMI is interpreted using fixed numerical ranges. Pediatric BMI is more complicated because children are growing. Clinicians compare a child’s BMI with growth-chart values for children of the same age and sex. The resulting percentile or percentage above the 95th percentile helps describe the severity of obesity.
A child can gain weight as they grow taller and still improve their BMI trajectory. For that reason, a single scale reading gives an incomplete picture. Pediatric specialists may look at height velocity, BMI percentile, the percentage above the 95th percentile, waist measurements, blood pressure, laboratory markers, physical function and overall wellbeing.
This is also why weight tracking in children should be guided by a clinician. Frequent weighing without a clear purpose can create anxiety or shame. The goal is to understand health and growth over time, not to turn every fluctuation into a verdict.
The topline release provides several useful facts:
Several important details remain unavailable:
Novo Nordisk has said detailed results are planned for presentation at ObesityWeek 2026 in November. Until those data are available, the 40.4% figure should be treated as an important early result rather than a complete clinical picture.
No—not for chronic weight management in the United States at the time of writing. The current US prescribing information for Wegovy includes adults and pediatric patients ages 12 and older with obesity. Safety and effectiveness for weight management have not been established in children under 12.
A successful trial does not automatically change the approved age range. The manufacturer must submit the evidence to regulators, who then review efficacy, safety, manufacturing and labeling. That process can lead to approval, a request for more information or no change.
Families should not use a trial announcement as a reason to obtain or give a child semaglutide without specialist care. Pediatric obesity treatment requires an individual assessment that considers growth, development, other health conditions, family circumstances and the child’s emotional wellbeing.
Novo Nordisk reported that STEP Young’s safety profile was consistent with previous semaglutide trials and that no new safety concerns were identified. That is reassuring, but it is not the same as proving long-term safety in every child.
Semaglutide commonly causes gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation and abdominal pain. Current prescribing information also includes warnings about pancreatitis, gallbladder problems, kidney injury related to dehydration, severe gastrointestinal reactions, serious allergic reactions, increased heart rate and other risks. It carries a boxed warning about thyroid C-cell tumors seen in rodents and should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Those label warnings come from the broader semaglutide evidence base and should not be mistaken for STEP Young-specific event rates. The full study presentation is needed to see which adverse events occurred in the younger participants, how often they occurred and whether they caused treatment discontinuation.
Children are not small adults. Between ages 6 and 11, their bodies are building bone, muscle and other tissues while moving toward puberty. Any treatment that changes appetite and energy intake must be evaluated in that context.
The sponsor reported no identified safety concerns related to growth or pubertal development in the topline analysis. That is encouraging, but detailed measurements and longer follow-up are still important. Researchers will need to examine height velocity, bone and lean-mass outcomes, nutritional adequacy and pubertal progression—not only weight reduction.
Preserving lean tissue is relevant at every age, but the conversation is especially sensitive in a growing child. A pediatric care team may include a physician, dietitian, behavioral-health professional and exercise specialist. Their goal is to support healthy development while treating obesity as a chronic disease.
STEP Young did not compare semaglutide alone with doing nothing. Children in both groups received support for a reduced-calorie diet and increased physical activity. This matters when interpreting the results.
Medication may reduce hunger and make behavior changes more manageable, but it does not replace adequate nutrition, movement, sleep or family support. For children, “lifestyle treatment” should never mean blame or rigid dieting. Effective care usually focuses on the household environment, regular meals, nutrient-dense foods, enjoyable activity and sustainable routines.
Families also need plans for common real-life situations: a child who feels too nauseated to eat breakfast, sports days when hydration matters, changes in appetite after a weekly injection, school meals and conversations with relatives who may comment on weight.
If semaglutide for younger children becomes an option in the future—or if a clinician is discussing any obesity treatment—these questions can help make the conversation more specific:
A clear record can help a specialist distinguish a temporary symptom from a repeated pattern. If a clinician has prescribed treatment and recommends home tracking, families may find it useful to record:
Seek medical guidance promptly for severe or persistent abdominal pain, repeated vomiting, signs of dehydration, a serious allergic reaction or any symptom the child’s care team has identified as urgent.
When a pediatric specialist is overseeing treatment, an adult caregiver can use Peptimize to keep a consistent record of confirmed doses, symptoms, appetite patterns, hydration, nutrition and clinician-directed measurements. The value is not in collecting as much data as possible. It is in making the information easier to review.
For example, a weekly timeline may show that nausea repeatedly peaks the day after treatment, that fluid intake is lower on school days or that appetite changes are affecting breakfast more than dinner. A concise pattern is easier to discuss at an appointment than a month of scattered notes.
Peptimize is a tracking tool, not a pediatric dosing guide or a substitute for medical care. Caregivers should record the plan provided by the treating clinician and use the record to ask better questions. Medication changes should always come from the child’s qualified care team.
The next major step is the detailed STEP Young presentation. The most useful data will include the average and distribution of BMI change, treatment discontinuations, adverse-event rates, growth and pubertal measures, body composition and cardiometabolic outcomes.
Longer-term evidence will matter even more. Obesity is a chronic condition, and a 68-week endpoint cannot tell us what happens over several years, throughout puberty or after medication is discontinued. Larger studies and real-world follow-up will be needed to identify uncommon risks and understand which children benefit most.
STEP Young provides the clearest evidence so far that semaglutide can substantially change BMI trajectories in some children ages 6 to 11 with obesity. It does not yet establish an approved treatment for this age group, answer every safety question or replace comprehensive pediatric care.
The right response is neither hype nor dismissal. It is careful attention to the full data, thoughtful specialist evaluation and organized tracking that keeps the child’s growth, health and wellbeing at the center.
This article is for education only and is not medical advice. Do not start, stop or change a child’s medication based on this article. Pediatric obesity treatment should be supervised by a qualified clinician who can assess growth, development, nutrition and individual risk.
Educational content only. Nothing here is medical advice, a diagnosis, or a dosing or titration recommendation. Decisions about any medication belong with you and your prescriber.
